Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI): down 9.37 percent to USD 0.6000, with a creditor forbearance period that ran to November 1, 2026.
  • Unicycive Therapeutics (NASDAQ:UNCY): down 9.09 percent to USD 3.40, with an FDA PDUFA date of March 25, 2027.
  • Celularity (NASDAQ:CELU): down 8.64 percent to USD 0.7310, after regaining Nasdaq reporting compliance on October 22, 2026.
  • Senti Biosciences (NASDAQ:SNTI): down 6.72 percent to USD 0.1540, with USD 8.9 million of cash at March 31, 2026.
  • Protalix BioTherapeutics (NYSEAMERICAN:PLX): down 7.34 percent to USD 2.40, with second quarter Revenue of USD 19.9 million.

Karyopharm Therapeutics (NASDAQ:KPTI): A Forbearance Deadline Has Passed

Karyopharm Therapeutics (NASDAQ:KPTI) was down 9.37 percent at USD 0.6000 in pre-market trading on November 2, 2026. No company announcement dated that day was identified. The nearest event is the end of a creditor forbearance period at 11:59 p.m. Eastern on November 1, 2026, per an 8-K dated October 22, 2026.

The company markets the oral cancer drug XPOVIO. Fiscal 2025 revenue was USD 146.1 million with a net loss of USD 196.0 million. Its notes carry conversion rights that could dilute shareholders, and no filing describing the outcome after November 1, 2026 was found. As a penny stock, it can swing sharply on thin liquidity.

Unicycive Therapeutics (NASDAQ:UNCY): Pullback Ahead of a March 2027 FDA Date

Unicycive Therapeutics (NASDAQ:UNCY) was down 9.09 percent at USD 3.40 in pre-market trading on November 2, 2026, and no announcement dated that day was identified. A company release dated October 21, 2026 said the FDA accepted the resubmitted application for oxylanthanum carbonate and set a PDUFA goal date of March 25, 2027.

A PDUFA date is a review target and does not guarantee approval. Notices published on October 29 and 30, 2026 described a securities class action, and these are allegations. As a clinical-stage Penny Stock without product revenue, it may need further capital, which can dilute holders.

Celularity (NASDAQ:CELU): Compliance Restored, Shares Still Dip

Celularity (NASDAQ:CELU) was down 8.64 percent at USD 0.7310 in pre-market trading on November 2, 2026. No announcement dated that day was identified. Profit taking after a volatile run is one plausible factor, though that is an inference and not a company statement.

A release dated October 22, 2026 said the company regained compliance with Nasdaq's periodic reporting rule after filing its June 30, 2026 Quarterly Report on October 20, 2026. A September 24, 2026 Recapitalization carries notes with an initial conversion price of USD 1.50 per share. Later closings are not assured, and conversions or additional raises could dilute shareholders in this penny stock.

Senti Biosciences (NASDAQ:SNTI): Sub-Cent Moves and a Thin Cash Cushion

Senti Biosciences (NASDAQ:SNTI) was down 6.72 percent at USD 0.1540 in pre-market trading on November 2, 2026. Searches of company releases and filings dated late October to November 2, 2026 did not identify an announcement explaining the decline, so it should be read as price action.

The lead program, SENTI-202, holds Orphan Drug and RMAT designations, and the company plans a pivotal trial in relapsed or refractory acute myeloid leukemia. Cash was USD 8.9 million at March 31, 2026, against operating cash burn of USD 7.5 million for the quarter. That covers a little over one quarter of burn at that rate (calculated), so funding and dilution matter for this penny stock.

Protalix BioTherapeutics (NYSEAMERICAN:PLX): Slipping Before an Investor Conference

Protalix BioTherapeutics (NYSEAMERICAN:PLX) was down 7.34 percent at USD 2.40 in pre-market trading on November 2, 2026. The previous close was about USD 2.59 (calculated). No release or filing dated that day was identified, so no specific catalyst can be assigned.

Second quarter 2026 revenue was USD 19.9 million with Net Income of USD 3.8 million, and the company reaffirmed 2026 revenue guidance of USD 78.0 million to USD 83.0 million. Cash and short-term bank deposits were USD 40.7 million at June 30, 2026. Its chief executive presents on November 10, 2026. Shares below USD 5 can be volatile and less liquid.

Where Things Stand

The five declines ranged from 6.72 percent to 9.37 percent, and only Karyopharm had a dated event close to the session, the end of its forbearance period. For the rest, no announcement from November 2, 2026 was identified, so the moves may reflect thin pre-market trading more than news. Several of these penny stocks share funding and dilution questions, from convertible notes to short cash runways.

Next markers include any Karyopharm filing on its creditors, the Protalix presentation on November 10, 2026, Celularity's September 30, 2026 quarterly filing, and the Unicycive PDUFA date of March 25, 2027. Pre-market prints on low Volume can reverse once regular trading opens.